GEO-CM04S1: A Dual-Antigen COVID-19 Vaccine for Immunocompromised Patients

Abstract

The multiantigen design and viral vector delivery platform of GEO-CM04S1 position this vaccine candidate as a next generation COVID-19 vaccine. Data generated to date indicate that the vaccine induces a durable, broadly specific and broadly functional humoral and cellular immune response to SARS-CoV-2 in both healthy adults and those with compromised immunity. The safety profile, as well as the breadth and magnitude of vaccine-induced T-cell responses supports its use in immunocompromised patients for prevention of severe COVID-19, addressing a critical unmet need. Targeting sequence-conserved structural proteins of this continually evolving pathogen should reduce the burdensome requirement for frequent updating and booster strategies designed to "chase the variant" to maintain efficacy.